Featured Publications
Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets
Hsu M, Jung O, Kwan L, Jegede O, Martin B, Malhotra A, Suzuki J. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. Journal Of Substance Use And Addiction Treatment 2023, 157: 209216. PMID: 37981243, DOI: 10.1016/j.josat.2023.209216.Peer-Reviewed Original ResearchOpioid use disorderSocioeconomic statusUse disordersCOVID-19 pandemicBuprenorphine/naloxoneActive substance useUse disorder treatmentPercent of participantsActive prescriptionMOUD accessSublingual buprenorphineOUD treatmentTreatment gapTreatment accessMOUDDisorder treatmentBuprenorphineAdverse effectsSubstance useVulnerable populationsIndividual-level factorsMedicationsAccess challengesWhite participantsDisorders
2022
Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder
Na PJ, Ralevski E, Jegede O, Wolfgang A, Petrakis IL. Depression and/or PTSD Comorbidity Affects Response to Antidepressants in Those With Alcohol Use Disorder. Frontiers In Psychiatry 2022, 12: 768318. PMID: 35058816, PMCID: PMC8765227, DOI: 10.3389/fpsyt.2021.768318.Peer-Reviewed Original ResearchPost-traumatic stress disorderAlcohol use disorderCo-occurring depressionHeavy drinking daysBetter drinking outcomesDrinking daysDiagnostic groupsDrinking outcomesDepressive symptomsUse disordersPercent heavy drinking daysPercent drinking daysRandomized control trialSerotonergic antidepressantsPTSD comorbidityControl trialDepression groupDepressive outcomesSignificant interactionOverall significant differenceDesipramineParoxetinePlaceboMedicationsComorbid MDD
2018
The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report
Azizi H, Zeng Y, Kallikkadan J, Kahn A, Olayinka O, Popoola O, Khan T, Rimawi D, Malik A, Williams S, Langdon S, Obegolu C, Nuthalapati D, Alzear R, Kalbouneh H, Mahbub A, Ojimba C, Oyelakin A, Kodjo K, Ferdous Saad A, Jegede O, Jolayemi A. The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report. International Journal Of Innovative Research In Medical Science 2018, 3 DOI: 10.23958/ijirms/vol03-i08/08.Peer-Reviewed Original ResearchNegative symptomsMesocortical pathwayStimulant medicationSymptom subscalesTwo-point reductionClasses of medicationsSecond-generation antipsychoticsPositive symptom subscaleThree-week trialNegative symptom subscaleAntipsychotic therapyNegative syndrome scoreGeneration antipsychoticsCase reportSyndrome scoreDopamine activityMedicationsSymptomsSchizophreniaThree-week periodScoresPotential benefitsSubscales